AzTrials
AzTrials

Multiple SclerosisNIBS_MSfNCT07842302

Fighting Fatigue in Multiple Sclerosis: TMS vs. tDCS Efficacy.

A study testing TMS and tDCS in people with Multiple Sclerosis, run by Universitat Oberta de Catalunya.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Multiple Sclerosis (MS) is a chronic neurological disease impacting 2.8 million individuals globally, with fatigue being its most debilitating symptom, reported by 75% of patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Sclerosis
What is being tested?
TMS and tDCS
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
No sites listed yet
Study dates
Sep 2026to Sep 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • MS diagnosis (relapsing-remitting form) according to 2024 McDonald criteria.
  • ≥ 18 years old
  • Expanded Disability Status Scale (EDSS) 1.5-4.5
  • Fatigue Severity Scale (FSS) >4 (mean score of all items)
  • No history of disease relapses in the previous 3 months
  • Be able to give informed consent.

Who cannot join

  • Any other neurological condition beyond MS
  • Another medical situation potentially associated with fatigue (e.g. sleep apnea, chronic fatigue syndrome, arterial hypertension)
  • Secondary epilepsy
  • Matching the exclusion criteria for TMS or tES application (history of epilepsy, metallic inserts in the head with the exception of titanium, pacemaker, electronic prosthesis or biostimulators, electrodes in the brain or spinal cord, dermatological problems) according to international safety guidelines (Antal et al., 2017; Lefaucheur et al., 2014; 2020; Rossi et al., 2021)
  • Pregnancy or possibility of pregnancy
  • Alcohol or other toxic abuse in the last year
Show all 9Show fewer
  • Major psychiatric disorders (eg, schizophrenia, bipolar disorder, etc.)
  • Inability to communicate or cognitive impairment
  • Change in medication in the previous 4 months

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Elena M Marron, PhD contact

+34620912976

emunozmarr@uoc.edu

About this study

Official title: Fighting Fatigue in Multiple Sclerosis: A Comparative Study of Magnetic vs. Electrical Non-invasive Brain Stimulation

Multiple Sclerosis (MS) is a chronic neurological disease impacting 2.8 million individuals globally, with fatigue being its most debilitating symptom, reported by 75% of patients. Despite its prevalence, the pathophysiology of MS-related fatigue remains poorly understood, and current pharmacological treatments have limited effectiveness. This research addresses this critical gap by investigating two non-invasive brain stimulation (NIBS) techniquestranscranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS)as innovative, effective and scalable therapeutic approaches for MS fatigue.

The study employs a parallel, randomized, triple-blind, multicentric, sham-controlled design to assess and compare the short- and long-term efficacy of TMS and tDCS in addressing MS-related fatigue. 80 participants will be recruited from multiple centers in Spain and randomly assigned to one of four experimental groups: TMS, tDCS, Sham-TMS, Sham-tDCS. Each intervention will consist of 20 sessions, conducted daily from Monday to Friday, over 4 weeks. The left dorsolateral prefrontal cortex (DLPFC, F3 following the 10/20 system for EEG) was selected as the stimulation site based on its involvement in MS-related self-reported fatigue and in cognitive fatigability. For TMS experimental groups, intermittent theta-burst protocol (iTBS) will be used to increase the cortical excitability of the stimulated area. iTBS delivers a total of 600 pulses, organised into 50 Hz triplets repeated at 5 Hz, with 2second blocks of pulses, interleaved with 8 seconds of rest, repeated 20 times (total duration: 190s). The intensity of stimulation will be individually tailored based on the active motor threshold (aMT), setting it at 80% of the aMT. The sham stimulation will follow the same protocol, but using a sham coil (placebo). For tDCS experimental groups anodal tDCS will be applied (increasing cortical excitability) with the anode over the left DLPFC (F3), and the cathode over the contralateral supraorbital area. The intensity will be 2mA, and the duration of the stimulation will be 20min per session. For tDCS placebo condition, the sham option available on the device will be selected.

Read more

Primary outcomes include changes in fatigue levels measured through MS validated self-report scales (Modified Fatigue Impact Scale-MFIS; Fatigue Scale for Motor and Cognitive Functions-FSMC); secondary outcomes include depression (Beck Depression Inventory-II, BDI-II), quality of life (Multiple Sclerosis Quality of Life, MSQOL-54), functional independence (Functional Independence Measure, FIM), and cognitive fatigability (Symbol Digit Modalities Test, SDMT). All the outcomes will be assessed at baseline, at the end of the intervention, and six months after the end of the treatment (6 months follow-up).

This project promotes personalized precision medicine and innovative new treatment methods. This research is expected to expand scientific knowledge on NIBS efficacy in MS, establish evidence-based clinical practices, and set the foundation for cost-effective, patient-centered therapies. The study also addresses gender-specific responses to treatment, ensuring inclusive therapeutic strategies. Furthermore, it has the potential to benefit other neurological conditions characterized by fatigue, such as stroke, chronic fatigue syndrome or Parkinsons disease, showing significant social, clinical, and economic impact.

Being tested
TMS, tDCS, Sham TMS, Sham tDCS
Keywords
Fatigue, Non-invasive brain stimulation, tDCS, transcranial direct current stimulation, TMS, transcranial magnetic stimulation
Medical subject headings
Multiple Sclerosis, Fatigue

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TMSDevice

    Intermitent theta burst stimulation over dorsolateral prefrontal cortex

  • tDCSDevice

    Transcranial direct current stimulation over dorsolateral prefrontal cortex

  • Sham TMSDevice

    Sham intermitent theta burst stimulation over dorsolateral prefrontal cortex

  • Sham tDCSDevice

    Sham transcranial direct current stimulation over dorsolateral prefrontal cortex

Study groups in NCT07842302
Study groupRoleWhat they receive
Active TMSExperimentaliTBS applied over left prefrontal dorsolateral cortex
Receives: Device: TMS
Sham TMSSham comparatorSham iTBS applied over left prefrontal dorsolateral cortex
Receives: Device: Sham TMS
Active tDCSExperimentaltDCS applied over left prefrontal dorsolateral cortex
Receives: Device: tDCS
Sham tDCSSham comparatorSham tDCS applied over left prefrontal dorsolateral cortex
Receives: Device: Sham tDCS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Modified Fatigue Impact Scale (MFIS)

    The MFIS is a 21-item self-report questionnaire designed to assess how fatigue impacts the daily lives of people living with Multiple Sclerosis (MS). It consists of 21 items divided into three subscales: Physical subscale (9 items)Cognitive subscale (10 items)Psychosocial subscale (2 items). Items are rated based on the patient's experiences over the past 4 weeks using a 5-point Likert scale (from 0 = "Never" to 4 = "Almost always"). Total score ranges from 0 to 84, with higher score indicating more severe fatigue.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  2. Fatigue Scale for Motor and Cognitive Functions (FSMC)

    It is a 20-item scale assessing two dimensions of MS-related fatigue: cognitive and motor. Patients rank statements on a scale from "Does not apply" to "Applies completely". Cut-off values were used to classify patients as experiencing mild, moderate or severe fatigue. Higher scores indicating a greater impact of fatigue.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  3. Multiple sclerosis fatigue severity scale (MSFSS)

    It is a 9-item (7-point Likert scale), self-report, questionnaire designed to measure the severity of fatigue and its impact on daily activities. It is one of the most widely used and validated scales for patients with Multiple Sclerosis. Higher score Indicates more severe fatigue and interference with the patient's daily responsibilities, work, or social life.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  4. Symbol Digit Modalities Test (SDMT)

    The SDMT measures information processing speed, visual scanning, working memory, and sustained attention. It is widely considered the gold standard for detecting and tracking cognitive impairment in patients with Multiple Sclerosis. The total score ranges from 0 to 110, with higher score indicating better cognitive performance.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

Secondary outcomes (10)
  1. Multiple Sclerosis Quality of Life (MSQOL-54)

    It is a highly comprehensive, disease-specific health-related quality of life instrument designed for patients with Multiple Sclerosis. It consists of 54 items divided into 12 distinct subscales alongside 2 single items.The 12 Subscales: Physical function, role limitations (physical), role limitations (emotional), pain, emotional well-being, energy/fatigue, health perceptions, social function, cognitive function, health distress, sexual function, and satisfaction with sexual function. Total score ranges from 0 to 100, where higher scores indicate a better quality of life.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  2. Functional Independence Measure (FIM)

    It is an 18-item clinician-administered assessment designed to measure a patient's level of disability and track their functional changes during rehabilitation. It quantifies how much assistance a person requires to perform essential activities of daily living safely. It is divided into two main subscales: Motor Subscale (13 items): Covers self-care, sphincter control, transfers, and locomotion; and Cognitive Subscale (5 items): Covers communication and social cognition (problem-solving, memory). Total score ranges from 18 to 126. Higher scores indicate greater functional independence.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  3. Barther Index

    The Barthel Index is an internationally recognized, clinician-administered or self-report rating scale used to measure a patient's performance in activities of daily living. It consists of 10 items evaluating basic self-care and mobility tasks. The 10 Items: Feeding, bathing, grooming, dressing, bowel control, bladder control, toilet use, transfers (bed to chair), mobility (on level surfaces), and stairs. Total score ranges from 0 to 100; higher scores indicate greater independence.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  4. Selective reminding test (SRT)

    The SRT is a highly sensitive neuropsychological verbal memory test designed to assess verbal learning and long-term memory. It is uniquely structured to differentiate between a patient's ability to store information over the long term versus their ability to retrieve it at any given moment. It is widely used to detect cognitive impairment in Multiple Sclerosis. It consists of 6 consecutive learning trials, followed by a delayed recall trial (administered 15 to 30 minutes later) and a final recognition trial. Instead of a single final number, the SRT generates multiple crucial metrics: Long-Term Storage (LTS): The number of words that have entered long-term memory.Consistent Long-Term Retrieval (CLTR): The words consistently recalled across consecutive trials without being reminded.Short-Term Storage (STS): Words recalled only after just being read. Higher scores in all indices indicate better verbal memory and learning capacity.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  5. Spatial recall test (10/36 SPART)

    The 10/36 SPART is a highly sensitive neuropsychological test used to evaluate visuospatial learning and long-term visual memory. It includes two different scores: immediate recall ranges from 0 to 30; and delayed recall ranges from 0 to 10. Higher scores always indicate better visuospatial memory.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  6. Paced auditory serial addition task (PASAT)

    The PASAT is used to assess auditory information processing speed, sustained attention, divided attention, and working memory. The final score ranges from 0 to 60, with higher scores indicate better processing speed and working memory.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  7. Word List Generation Test (WLG)

    The WLG is a brief, widely used verbal fluency test designed to assess a patient's spontaneous word production, executive functioning, and mental flexibility. It includes both phonemic (phonetic) and semantic (categorical) verbal fluency tasks. The final score is simply the total number of correct, unique words produced within the time limit. Higher scores indicate better verbal fluency and executive functioning.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  8. Stroop test

    The Stroop Test is used to evaluate executive functioning, specifically selective attention, cognitive flexibility, and processing speed. It measures a person's ability to inhibit an automatic response (reading a word) in favor of a novel, controlled response (naming the ink color). The standard clinical version consists of three separate trials, each presented on a page with columns of items:Word Page (W): Color words (e.g., RED, GREEN, BLUE) printed in black ink. The patient reads the words as fast as possible.Color Page (C): Rows of symbols (like XXXX) printed in colored ink. The patient names the ink colors as fast as possible.Color-Word Page (CW / Interference): Color words printed in conflicting ink colors (e.g., the word RED printed in BLUE ink). The patient must name the color of the ink and ignore the written word. The Interference Score indicate resistance to interferences, with higher scores indicating better cognitive control and stronger resistance to interference.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  9. Trail making test (A and B)

    The Trail Making Test (TMT) is a widely used neuropsychological assessment designed to evaluate visuospatial scanning, processing speed, and executive functioning (specifically cognitive flexibility and set-shifting).

    Part A (TMT-A): The patient is presented with a sheet containing the numbers 1 through 25 scattered inside circles. They must draw a continuous line connecting the numbers in sequential order (1-2-3-4...). It primarily measures visual scanning, motor speed, and basic processing speed.

    Part B (TMT-B): The patient is presented with numbers (1 to 13) and letters (A to L) scattered inside circles. They must draw a continuous line alternating between numbers and letters in ascending order (1-A-2-B-3-C...). It measures complex executive control, working memory, and cognitive flexibility (set-shifting).

    The score for each part is the total time in seconds taken to complete the task. Lower times indicate better cognitive performance (faster speed and efficiency).

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

  10. Hospital anxiety and depression scale (HADS)

    The HADS is a widely used 14-item (rated on a 4-point Likert scale, 0 to 3) self-report questionnaire designed to screen for anxiety and depression in patients with physical medical conditions. Its primary methodological advantage is that it strictly excludes somatic symptoms (such as fatigue, pain, or sleep disturbances). This prevents a patient's physical illness-such as Multiple Sclerosis-from artificially inflating their psychological scores.

    It features two independent subscales of 7 items each:HADS-A (Anxiety): Evaluates cognitive and emotional states of tension, worry, and panic.HADS-D (Depression): Heavily focused on anhedonia (the loss of the ability to enjoy things) rather than physical lethargy.

    Each subscale is calculated separately and ranges from 0 to 21. Higher scores indicate worse psychological distress.

    Measured: Baseline, post-treatment (1 month), and 6 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionMay 2029 (estimated)
  4. Study completionSep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07842302
Sponsor's protocol ID
NIBS_MSf
Other IDs
PID2024-161367OB-I00
Acronym
NIBS_MSf
Status last verified
Sep 2026
First submitted
20 Jul 2026
Last updated
25 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing TMS and tDCS in people with Multiple Sclerosis, run by Universitat Oberta de Catalunya.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Elena M Marron, PhD (+34620912976, emunozmarr@uoc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Modified Fatigue Impact Scale (MFIS) (time frame: Baseline, post-treatment (1 month), and 6 months follow-up). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in